Stocks · Conviction
Medium conviction · 395 research notes
395 stocks our research rates Medium: more likely to lead the S&P 500 over the next three months, by a modest margin. Each has a dated research note with its thesis, kill line and next catalyst.
All 395 have a dated research note with a published kill line: the note's own test, stated in advance, of what would prove it wrong: a price level, a business fact, or both.
All stocksAPPNAppianMedium Appian's third-quarter 2026 revenue rose 25% to $234.6 million and full-year guidance went up again, giving the shares a modest edge over the S&P 500; the fourth-quarter report, expected around 18 February 2027, shows whether cloud…CHYMChime FinancialMedium Chime Financial's revenue growth sped up to 32% and its 2026 outlook rose a third time, giving the shares a modest edge over the S&P 500 over three months; the fourth-quarter 2026 report, against a $757–767 million forecast, settles it.ETONEton PharmaceuticalsMedium Eton Pharmaceuticals is modestly more likely than not to beat the S&P 500 over three months, after third-quarter revenue of $57.9 million, up 158%, lifted its 2026 guide above $175 million. The fourth-quarter report, expected around…IMAXMedium IMAX Corporation's shares are modestly more likely than not to beat the S&P 500 over three months on a record third quarter and a raised margin target; Dune: Part Three's 18 December 2026 opening and 2027 box-office guidance due early 2027…KNSAKiniksa Pharmaceuticals InternationalMedium Kiniksa Pharmaceuticals is modestly more likely than not to beat the S&P 500 over three months on its third 2026 ARCALYST guidance raise, to $1.045–1.050 billion. Fourth-quarter sales and the first 2027 range, due in the early-2027 results…LLYEli LillyMedium Eli Lilly's shares are more likely than not to beat the S&P 500 over three months, as tirzepatide volume still outruns price cuts and Foundayo won China approval on 12 November 2026. The fourth-quarter report and 2027 outlook, expected…MSFTMicrosoftMedium Microsoft's shares are modestly more likely to lead the S&P 500 over three months because Azure grew 48% in the September quarter and is guided to 49–50% for December. The fiscal second-quarter report, expected in late January 2027, shows…PLMRPalomar HoldingsMedium Palomar Holdings is more likely than not to beat the S&P 500 over three months because estimates keep rising after its fourth 2026 guidance raise, to $280–285 million of adjusted net income. The fourth-quarter report, expected around…QNSTQuinStreetMedium QuinStreet's shares are more likely than not to beat the S&P 500 over three months after it beat guidance and raised its fiscal 2027 outlook on 4 November 2026; the early-February 2027 report shows whether insurance-carrier ad spending…UUnity SoftwareMedium Unity Software's advertising turnaround and reported takeover interest make the shares modestly more likely than not to beat the S&P 500 over three months; the fourth-quarter 2026 report, expected around 11 February 2027, settles whether…XERSXeris Biopharma HoldingsMedium Xeris Biopharma's shares are modestly more likely than not to beat the S&P 500 over three months because Recorlev sales rose 93% to $71.5 million in the third quarter and 2026 revenue guidance rose to $395–405 million. Preliminary…ZETAZeta Global HoldingsMedium Zeta Global's shares hold a modest edge over the S&P 500 after the company beat its third-quarter guide and raised 2026 revenue guidance to $1.853 billion–$1.857 billion on 9 November 2026; the fourth-quarter report, expected in February…AAMIAcadian Asset ManagementMedium Acadian Asset Management's eleven straight quarters of client inflows, record fees and resumed buybacks give its shares a modest edge over the S&P 500. The fourth-quarter report, expected in late January 2027, shows whether flows stay…AAPLAppleMedium Apple's above-consensus 7–10% December-quarter revenue guide gives the shares a modest edge over the S&P 500. The fiscal first-quarter report due around late January 2027 settles it by showing whether iPhone Duo sales outrun memory costs…ABBVAbbVieMedium AbbVie's Skyrizi and Rinvoq, each up more than 22% in the 30 October 2026 third-quarter report, keep lifting guidance and analyst targets, so the shares modestly favour beating the S&P 500. The fourth-quarter report expected around 29…ADMAADMA BiologicsMedium ADMA Biologics' ASCENIV immune globulin grew 31% in Q3 2026 and profit guidance was raised, though revenue guidance stayed at "at least $530 million"; fourth-quarter ASCENIV demand and pricing settle whether the post-report gain holds.ADPTAdaptive BiotechnologiesMedium Adaptive Biotechnologies is more likely than not to beat the S&P 500 over three months because clonoSEQ tests rose 46% in the third quarter of 2026 and MRD revenue guidance rose to $276–286 million. Medicare's final 2027 lab rates,…AGLagilon healthMedium agilon health roughly doubled its 2026 adjusted EBITDA guidance to $145–$155 million after a second profitable quarter, giving the shares a modest edge over the S&P 500; the 17 November 2026 investor event and the Q4 report show whether…ALGTAllegiant TravelMedium Allegiant Travel Company is modestly more likely to beat the S&P 500 over three months as fares outrun fuel; its 7 December 2026 investor day shows whether 2027 targets back the above-$6.00 2026 earnings guide.AMDAdvanced Micro DevicesMedium Advanced Micro Devices is modestly more likely than not to beat the S&P 500: Helios AI racks and doubling server-processor sales back a $17 billion fourth-quarter guide and more than 80% revenue growth forecast for 2027. AMD's…AMGNAmgenMedium Amgen is modestly more likely than not to beat the S&P 500 over three months because Repatha, Evenity and newer drugs are outgrowing biosimilar losses. The fourth-quarter report and 2027 outlook, expected in early February 2027, settle it.AMZNAmazon.comMedium Amazon.com's shares are modestly more likely to beat the S&P 500 over three months as AWS revenue grew 39% last quarter on a $578 billion backlog; Anthropic's IPO pricing, expected around 18 November 2026, and the fourth-quarter report…ANETArista NetworksMedium Arista Networks' guide for about $18.5 billion of 2027 revenue, near 40% growth, gives its shares a modest edge over the S&P 500 after a rebound to $206.63 on 12 November 2026. Nvidia's 17 November 2026 results set the tone for AI…APOGApogee EnterprisesMedium Apogee Enterprises' shares are modestly more likely to beat the S&P 500 because pricing and cost gains lifted fiscal 2027 adjusted EPS guidance to $3.00–$3.40 on 6 October 2026. The report expected around 6 January 2027 shows whether those…APPAppLovinMedium AppLovin's third-quarter 2026 revenue rose 55% to $2.185 billion and put growth back on track. The fourth-quarter report, expected around February 2027, shows whether its partly rolled-out ad models hold growth above the guided 43–44%.ARHSArhausMedium Arhaus's furniture orders are running far ahead of deliveries, giving the shares a modest edge over the S&P 500: Q3 2026 comparable written sales rose 13.9% and client deposits reached $325.0 million. The Q4 2026 report, expected in late…ARXSArxisMedium Arxis, a defense, space and industrial component roll-up, is modestly likely to beat the S&P 500 after 29% organic growth and a raised outlook on 28 October 2026. Its fourth-quarter report, due about late February 2027, tests whether…AVEXAEVEXMedium AEVEX's core drone and maritime business is outgrowing its fading Ukraine work, making the shares modestly likely to beat the S&P 500 over three months. First orders under its nearly $400 million drone contract and the 2027 outlook at the…AVGOBroadcomMedium Broadcom's shares look modestly more likely to beat the S&P 500 over three months as Nvidia's CEO exit and Anthropic's near-priced IPO draw buyers to its custom AI chips. The 9 December 2026 fourth-quarter report, against a $21.7 billion…AVTRAvantorMedium Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins fell. The 8 December 2026 Investor Day shows whether margin targets support further gains in the…AXGNAxogenMedium Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest edge over the S&P 500; the Q4 2026 report settles whether revenue excluding BioCircuit reaches the…BHCBausch Health CompaniesMedium Bausch Health's recovery is backed by a third-quarter beat and a second guidance raise on 28 October 2026, but $20.2 billion of debt principal keeps the shares highly sensitive; the fourth-quarter report, expected in early 2027, tests the…BTSGBrightSpring Health ServicesMedium BrightSpring Health Services is growing profit faster than revenue, with third-quarter 2026 adjusted EBITDA up 42% on specialty pharmacy margins and acquired home-health branches. Its first 2027 guidance, expected around late February…BWLPBW LPGMedium BW LPG Limited's shares are more likely to beat the S&P 500 because about 92% of third-quarter ship days were booked near $88,000 a day against $74,000 realised in the second quarter; the 24 November 2026 report shows whether earnings and…CCitigroupMedium Citigroup is modestly more likely to beat the S&P 500 over three months: its returns beat its 11% target while the shares fell 10.5% on market-wide selling. The mid-January 2027 fourth-quarter report shows whether returns and buybacks hold.CBRSCerebras SystemsMedium Cerebras Systems is modestly more likely to beat the S&P 500 over three months after guiding fourth-quarter core revenue to $310–330 million, above the $271 million consensus, and adding Microsoft as a cloud customer. The fourth-quarter…CDNACareDxMedium CareDx's shares are modestly more likely than not to beat the S&P 500: transplant testing revenue grew 39% in the third quarter excluding catch-up collections and 2026 guidance rose to $520–530 million. CMS's final 2027 Medicare rates, due…CDRECadre HoldingsMedium Cadre Holdings' 30% third-quarter sales jump to $202.9 million, 10% organic growth and first $100 million buyback give the shares a modest edge over the S&P 500. The early-March 2027 fourth-quarter report settles whether sales hold near…CEGConstellation EnergyMedium Constellation Energy's third-quarter beat and raised $12.50–$12.80 guidance make its shares modestly more likely than not to beat the S&P 500; whether data-center limits spread into its mid-Atlantic states and the February report settle it.CHAChagee HoldingsMedium Chagee Holdings is modestly more likely to lead the S&P 500 over three months: its shares cleared $14.00 on a $1.95 special dividend. The third-quarter report, expected around 27 November 2026, shows whether China same-store sales, down…CHDNChurchill DownsMedium Churchill Downs' growing Kentucky machine profit, record third quarter and $750 million buyback outweigh its shrinking Virginia machine revenue; monthly state figures and the fourth-quarter report expected around 25 February 2027 decide…CMCOColumbus McKinnonMedium Columbus McKinnon's Kito Crosby merger is beating profit forecasts and its chief executive bought shares after the 3 November 2026 guidance raise; the fiscal third-quarter report, expected in early February 2027, must show leverage falling…COAGHemab Therapeutics HoldingsMedium Hemab Therapeutics is modestly more likely than not to beat the S&P 500 over three months: its pivotal sutacimig trial has started and cash is guided into 2029. Updated Factor VII deficiency data at the ASH meeting on 14 December 2026 test…COSTCostco WholesaleMedium Costco Wholesale's underlying sales growth held at 7.3% in October and a $30 special dividend followed on 10 November 2026, giving the shares a modest edge over the S&P 500. The November sales report (~2 December 2026) and first-quarter…CPRICapri HoldingsMedium Capri Holdings' Michael Kors turnaround gives the shares a modest edge over the S&P 500 after the 30 October 2026 beat-and-raise, despite a CEO handover on 4 January 2027. The fiscal third-quarter report, expected in early February 2027,…CRLCharles River Laboratories InternationalMedium Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised guidance, and the $470 million Frontage deal adds clinical testing; the fourth-quarter report,…CROXCrocsMedium Crocs, Inc. is more likely to lead the S&P 500 over three months: a third-quarter beat and a third guidance raise lifted full-year adjusted EPS to $14.45–$14.65, and the fourth-quarter report due around mid-February 2027 settles it.CRSRCorsair GamingMedium Corsair Gaming's recovery case holds after it beat third-quarter guidance and raised its 2026 outlook on 5 November 2026; the fourth-quarter report shows whether profit holds as memory gross margin falls to 18%–20%.CRWVCoreWeaveMedium CoreWeave's third-quarter beat and 26% higher profit guide on 10 November 2026 give its shares a modestly better-than-even case against the S&P 500; the debt-funding plan, Microsoft's supplier review and Nvidia's leadership change decide…CSTLCastle BiosciencesMedium Castle Biosciences raised 2026 revenue guidance to $385–395 million and held its 50–52% TissueCypher volume growth plan; the fourth-quarter report, expected around 26 February 2027, shows whether that test offsets weaker melanoma volume.CVNACarvanaMedium Carvana is taking share in a flat used-car market, with third-quarter retail units up 39% and more units guided for the fourth quarter. The February 2027 report shows whether volume growth outruns falling profit per car.CVSCVS HealthMedium CVS Health is modestly more likely to beat the S&P 500 over three months: Aetna's costs improved and 2026 guidance rose, and the February 2027 report tests the 2027 outlook of at least $8.65 per share.CYRXCryoPortMedium Cryoport's cold-chain business for cell and gene therapies is growing faster and posted a second positive adjusted EBITDA quarter, with 2026 revenue guidance raised to $197–199 million. The fourth-quarter report settles whether that pace…DCTHDelcath SystemsMedium Delcath Systems' shares are more likely than not to beat the S&P 500 after third-quarter revenue of $35.1 million lifted 2026 guidance to $115–117 million on 9 November 2026; the full-year report, expected around March 2027, shows whether…DHRDanaherMedium Danaher's shares have a modest edge over the S&P 500 because mid-teens bioprocessing orders should reach revenue in 2027. Formal 2027 guidance in late January settles whether growth meets or beats the 4%–5% starting point that management…DUOLDuolingoMedium Duolingo's shares have a modest edge over the S&P 500 because daily user growth reaccelerated to 29% while 2026 guidance rose; the February 2027 report decides whether those users lift bookings growth above this year's 12%.DXCMDexComMedium Dexcom's raised 2026 outlook and 25.3% third-quarter operating margin give the shares a modest edge after a diabetes-device sell-off erased the post-report gain. A Medicare coverage decision for non-insulin type 2 diabetes, which…ECOOkeanis Eco TankersMedium Okeanis Eco Tankers is modestly more likely than not to beat the S&P 500, as fourth-quarter bookings of 71% of fleet days at about $420,000 a day exceed its record third quarter. The February 2027 fourth-quarter report shows whether rates…ELEstee Lauder CompaniesMedium Estée Lauder's turnaround now shows in sales as well as margins, with first-quarter organic sales up 6% and the fiscal 2027 outlook raised; the second-quarter report, estimated for about 3 February 2027, shows whether growth holds against…ELFe.l.f. BeautyMedium e.l.f. Beauty's shares are modestly more likely than not to beat the S&P 500 because the company raised its fiscal 2027 organic sales growth outlook to 9%–11% after 51% quarterly sales growth. The fiscal third-quarter report, expected…EMBCEmbectaMedium Embecta Corp. shares are modestly favored to beat the S&P 500 as higher margins and debt repayment outweigh shrinking U.S. pen-needle sales; the fiscal 2026 report and first fiscal 2027 outlook on 24 November 2026 settle it.ENOVEnovisMedium Enovis Corporation's orthopedic turnaround passed its 5 November 2026 test with 4.6% organic growth, raised earnings guidance and a $200 million buyback. The late-February 2027 full-year report shows whether about 5% growth and at least…EPAMEPAM SystemsMedium EPAM Systems is modestly more likely than not to beat the S&P 500 as its $1.8 billion buyback, including a $500 million UBS repurchase signed 9 November 2026, shrinks the share count; the February 2027 outlook shows whether organic growth…ETSYMedium Etsy's marketplace is growing faster than its own guidance, with third-quarter GMS up 8.8% and buyers growing again, giving the shares a modest edge over the S&P 500. Holiday sales against the $3.46–$3.52 billion fourth-quarter guidance…EVCEntravision CommunicationMedium Entravision's ad-technology unit grew 133% in the third quarter, beating its own guide, and the shares have held the gain; the fourth-quarter report in early 2027 settles whether ATS growth stays above 100%.EVEREverQuoteMedium EverQuote's third-quarter revenue of $218.1 million and adjusted EBITDA of $35.5 million beat the top of its guidance, giving the shares a modest edge over the S&P 500; the fourth-quarter report shows whether profit holds within a lower…EVHEvolent HealthMedium Evolent Health's margin repair now has evidence: Q3 medical costs fell to 93.0% of revenue and 2026 adjusted EBITDA guidance rose to $130–135 million. The late-February Q4 report, with its 2027 range, decides whether the $150 million-plus…FFord MotorMedium Ford Motor's raised 2026 profit guidance and roughly flat 2027 profit target give its shares a modestly better-than-even case to beat the S&P 500; the fourth-quarter report, expected in early February 2027, settles whether that target…FIGSMedium FIGS, the healthcare-apparel maker, holds a modest edge over the S&P 500 after beating third-quarter estimates and raising its 2026 outlook on 5 November 2026, although its CEO sold $79.7 million of stock on 9 November 2026. The…FISVFiservMedium Fiserv's revenue decline has levelled off and management is cutting costs and selling or shutting weak units; the fourth-quarter report, expected around February 2027, settles whether Merchant Solutions returns to its guided 6% to 8%…FLYFirefly AerospaceMedium Firefly Aerospace's third-quarter beat, raised revenue floor and record $1.7 billion backlog make its shares modestly likely to beat the S&P 500; the fourth-quarter Alpha Block II debut settles whether launches carry the $440–450 million…FPSForgent Power SolutionsMedium Forgent Power Solutions is modestly more likely than not to beat the S&P 500 over three months, after beating guidance and guiding fiscal second-quarter revenue to $560–590 million on 12 November 2026; the mid-March 2027 report settles…FTDRfrontdoorMedium Frontdoor's shares are modestly more likely to beat the S&P 500 over three months because renewal pricing, HVAC upgrades and a new $1 billion buyback lift per-share earnings far faster than its 1% member growth. The fourth-quarter report…GDYNGrid Dynamics HoldingsMedium Grid Dynamics' AI work is lifting the IT-services firm back toward double-digit growth at margins near 20%, which favors the shares beating the S&P 500. The Q4 2026 report, expected around late February 2027, shows whether 2027 guidance…GENGen DigitalMedium Gen Digital's raised fiscal 2027 outlook and its step back from a large GoDaddy deal give the shares a modest edge over the S&P 500; the Q3 FY27 report in early 2027 tests the $5.465–5.515 billion revenue range.GICGlobal IndustrialMedium Global Industrial Company's sales strategy is delivering high-single-digit daily sales growth and wider operating margins even without tariff refunds. The fourth-quarter report, expected around late February 2027, settles whether that…GKOSGlaukosMedium Glaukos's iDose TR glaucoma implant and Epioxa keratoconus therapy lifted third-quarter 2026 sales 58% to $211.0 million, giving the shares a modest edge on a $1 billion 2027 outlook. Medicare's pending iDose TR coverage decision and…GMABGenmab A/SMedium Genmab's own cancer drugs are becoming a second engine beside its DARZALEX royalty, with three launches targeted for 2027. ASH data on 14 December 2026 and the 16 December 2026 R&D update show whether filings stay on track.GMEGameStopMedium GameStop's shares hold modestly better-than-even odds of beating the S&P 500 on CEO Ryan Cohen's buying, $5.1 billion of cash and a 43.4 million-share eBay stake. The third-quarter report, projected for about 8 December 2026, settles…GPNGlobal PaymentsMedium Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results on 5 November 2026; a signed deal at a premium, or word that talks have ended, settles the case.GRNTGranite Ridge ResourcesMedium Granite Ridge Resources has returned production to its guided range and targets about 10% output growth in 2027 on roughly flat spending; its fourth-quarter report and first 2027 guidance, expected around early March 2027, show whether the…GTLBGitLabMedium GitLab's case is that Flex, its usage-based pricing for AI coding agents, lifts fiscal Q3 revenue above the $281–$283 million guidance. The fiscal Q3 report, expected about 1 December 2026, settles it.HAEHaemoneticsMedium Haemonetics' plasma revenue grew 17.7% organically before the CSL Plasma conversion added much, so the larger CSL gain lies ahead; the fiscal third-quarter report around 4 February 2027 shows whether it arrives without a further margin cut.HASHasbroMedium Hasbro's Magic: The Gathering profits and its raised 2026 outlook make the shares modestly more likely than not to beat the S&P 500 over three months. Holiday toy sales from 27 November 2026 and the fourth-quarter report expected around 17…HIPOHippo HoldingsMedium Hippo Holdings has modestly better-than-even odds of beating the S&P 500 after it raised 2026 profit guidance on 29 October 2026 on a falling expense ratio. Fourth-quarter underwriting against its 97–98% combined ratio guidance settles the…HNGEHinge HealthMedium Hinge Health's shares can lead the S&P 500 on 52% revenue growth and a raised $879–881 million 2026 guide; the February 2027 report must show fourth-quarter revenue of at least $249 million to keep the case.HNSTHonestMedium The Honest Company is modestly more likely than not to beat the S&P 500 over three months on record margins and a raised 2026 outlook; the fourth-quarter report, expected around March 2027, settles whether organic growth holds the guided…HTFLHeartflowMedium Heartflow's shares are modestly more likely to beat the S&P 500 over three months: third-quarter revenue rose 57% and the 2026 outlook was raised to $262–264 million, though the shares fell 19.13% on 13 November 2026. The fourth-quarter…HUMHumanaMedium Humana's third-quarter cost beat and higher $9.50 adjusted EPS floor, reported 6 November 2026, make its shares modestly more likely than not to beat the S&P 500 as the Star Ratings recovery lifts 2028 margins. The 10 December investor…ICLRICONMedium ICON plc's orders have recovered into fee-earning work, with a third-quarter direct-fee book-to-bill near 1.3, giving the shares a modest edge over the S&P 500 while earnings per share still trail last year. The fourth-quarter report and…INNSummit Hotel PropertiesMedium Summit Hotel Properties looks modestly more likely than not to beat the S&P 500: it raised 2026 guidance again on 3 November 2026 and October RevPAR rose about 5.5%. The late-February 2027 report shows whether fourth-quarter growth held…INTUIntuitMedium Intuit's shares hold a modest edge over the S&P 500 as AI agents, Credit Karma Tax and the Sequence deal target price-driven customer losses; the 19 November 2026 fiscal Q1 report settles it against the $4.294–$4.313 billion revenue guide.IQVIQVIA HoldingsMedium IQVIA's clinical-research bookings are outpacing revenue, with third-quarter 2026 bookings up 15% at a 1.2x book-to-bill and guidance raised. The 1 December 2026 investor day decides whether that becomes faster 2027 revenue growth.IRONDisc MedicineMedium Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19 October 2026, answering the FDA's February rejection. ASH pipeline data from 12 December 2026 and…KRMNKarman HoldingsMedium Karman Space & Defense's 66% revenue growth and $1.7 billion backlog make its shares, 66% below their January high, more likely than not to beat the S&P 500. The fourth-quarter report and 2027 outlook, expected around March 2027, settle…KVYOKlaviyoMedium Klaviyo's third-quarter revenue beat, raised 2026 guidance and new $300 million buyback make its shares modestly likely to beat the S&P 500. Fourth-quarter revenue against the $421–425 million guide and the first 2027 outlook settle it.LHLabcorp HoldingsMedium Labcorp's 11.5% Central Labs growth and raised 2026 guidance make its shares modestly more likely to beat the S&P 500 over three months. Final 2027 Medicare lab rates, due from CMS in late November 2026, test the case, and the February…LINDLindblad Expeditions HoldingsMedium Lindblad Expeditions' shares are modestly more likely than not to beat the S&P 500 as 91% occupancy, 6% higher pricing and record 2027 bookings lift profit. The fourth-quarter report and 2027 outlook, expected around late February 2027,…LMTLockheed MartinMedium Lockheed Martin's record $292.0 billion backlog and raised 2026 guidance make the shares modestly more likely than not to beat the S&P 500 after their post-midterm rebound. The 11 December 2026 federal funding deadline shows whether…LQDALiquidiaMedium Liquidia Corporation's shares are modestly more likely to beat the S&P 500 because YUTREPIA sales rose 31% to $222.7 million in the third quarter with record October shipments; preliminary fourth-quarter sales, due in early January 2027,…LUNRIntuitive MachinesMedium Intuitive Machines is modestly more likely than not to beat the S&P 500 over three months after record third-quarter revenue of $269.3 million and a $1.9 billion backlog. The 10-Q's count of at-the-market share sales tests the case, and…MAMastercardMedium Mastercard's card network and faster-growing services keep revenue rising at low double digits, giving its shares a modest edge over the S&P 500; the 16 November 2026 settlement hearing and the late-January report with 2027 guidance settle…MANEVeradermicsMedium Veradermics' hair-loss pill VDPHL01 has finished its male trials with clean 12-month safety and cash of $798.4M guided into 2030. The case now turns on when the company sets a new drug application date, with its 19 November 2026 Jefferies…MANHManhattan AssociatesMedium Manhattan Associates' cloud revenue grew 28% and its backlog 25% in the 27 October 2026 report, making the shares modestly more likely than not to beat the S&P 500. The fourth-quarter report and first 2027 guidance, expected around 27…MAXMediaAlphaMedium MediaAlpha's shares are modestly more likely than not to beat the S&P 500 over three months because insurers keep raising ad spending on its marketplace, shown by its 28 October 2026 beat and an 84% rise in home ad spend. The…MBGLMobility GlobalMedium Mobility Global, the CARFAX owner spun off from S&P Global, is more likely to beat the S&P 500 over three months because its third-quarter organic growth sped up to 7.6% and a $350–450 million buyback is due to start before the end of…MCDMcDonald'sMedium McDonald's US sales turned positive in September and improved through October after a value push, giving the shares a modest edge over the S&P 500; the fourth-quarter report in early 2027 shows whether US traffic has recovered.MCKMcKessonMedium McKesson's earnings keep beating its own guidance, which rose to $45.60–$46.40 of fiscal 2027 adjusted EPS on 4 November 2026; the fiscal third-quarter report, expected in early February 2027, shows whether profit growth holds as oncology…MGNIMagniteMedium Magnite's connected-TV growth beat guidance by a wide margin and lifted its 2026 outlook, giving the shares a modest edge over the S&P 500. The fourth-quarter report, estimated for late February 2027, shows whether growth holds once…MIRMirion TechnologiesMedium Mirion Technologies' nuclear power orders doubled and backlog reached $1.25 billion, supporting shares that lead the S&P 500 from a weak 2026. The mid-February 2027 report shows whether orders become revenue at better margins after the…MNSOMINISO Group HoldingMedium MINISO's 25%-30% mainland China sales growth, against a share price that already reflects lower full-year profit, gives the shares a modest edge; the 17 November 2026 third-quarter report shows whether margins stabilise.MRKMerckMedium Merck's newer drugs and under-the-skin Keytruda are carrying its growth after raised 2026 guidance on 29 October 2026; the early-February 2027 outlook shows whether moderate growth absorbs over $2 billion of generic losses.MRVIMaravai LifeSciences HoldingsMedium Maravai LifeSciences' 4 November 2026 third-quarter report beat estimates and raised full-year revenue and profit guidance, so reported numbers now support the rise in the shares. The fourth-quarter report decides whether the growth holds.MSMorgan StanleyMedium Morgan Stanley's shares have modestly better than even odds of beating the S&P 500, carried by its co-lead role on Anthropic's IPO and record wealth flows. The IPO pricing, reported for 18 November 2026, and the fourth-quarter report,…MTDMettler-Toledo InternationalMedium Mettler-Toledo's third-quarter beat and a 2027 earnings guide above estimates support modest outperformance against the S&P 500; the fourth-quarter report, expected in early February 2027, settles whether about 5% sales growth holds.MTWManitowocMedium Manitowoc's crane orders and raised 2026 guidance give the shares a modest edge over the S&P 500; the fourth-quarter report, expected around February 2027, settles whether about $90 million of fourth-quarter free cash flow arrives.MUMicron TechnologyMedium Micron Technology's shares look modestly more likely than not to beat the S&P 500, as its guidance and CoreWeave's 10 November 2026 outlook point to steady AI memory demand. Nvidia's 17 November 2026 results, its first under an interim…MYGNMyriad GeneticsMedium Myriad Genetics shares look modestly more likely to beat the S&P 500 after third-quarter revenue per test rose 1% and the 2026 revenue guide was raised; the cost of the 2 November 2026 network intrusion to testing volumes and patient data…NEONeoGenomicsMedium NeoGenomics' cancer-testing turnaround is lifting profit faster than revenue, but clinical test volume grew only 1.8% in the third quarter. Pending Medicare decisions on RaDaR ST and the fourth-quarter report will show whether volume…NSITInsight EnterprisesMedium Insight Enterprises' shares are modestly more likely than not to beat the S&P 500 because its raised 2026 earnings guidance ($13.55–$13.75 adjusted EPS) still outruns analysts' targets; the 2 December 2026 investor briefing and a mostly…NTSKNetskopeMedium Netskope's 29% revenue growth and raised fiscal 2027 outlook make the shares modestly more likely than not to beat the S&P 500, with RBC and Mizuho lifting targets in November. The 2 December 2026 fiscal Q3 report settles it: revenue must…OABIOmniAbMedium OmniAb is modestly more likely to beat the S&P 500 over three months because its raised 2026 guidance and $8.3 million of nine-month operating cash inflow show partners can fund its antibody-discovery model. The fourth-quarter report,…ODDODDITY TechMedium ODDITY Tech's third-quarter beat and raised 2026 outlook back a recovery built on steady IL MAKIAGE repeat orders and a growing SpoiledChild. The fourth-quarter report, expected in late February 2027, shows whether the advertising-partner…OLLIOllie's Bargain Outlet HoldingsMedium Ollie's Bargain Outlet shares are modestly more likely than not to beat the S&P 500, supported by a $500 million buyback and three analyst target increases since mid-October. The early-December third-quarter report shows whether comparable…ONONOn HoldingMedium On Holding's shares are rated modestly more likely to beat the S&P 500 because the company kept FY2026 sales guidance and plans faster fourth-quarter growth; holiday sales from 27 November 2026 and the Q4 report around March 2027 settle it.ONTOnterrisMedium Onterris's shares trade on a board-led strategic review that has engaged outside buyers and on a third-quarter cash flow recovery; a review outcome and fourth-quarter operating cash flow against the $30.0M–$40.0M guide settle the case.OPRTOportun FinancialMedium Oportun Financial's Q3 2026 beat and raised full-year guidance put its profit recovery on firmer ground as lending grows again; the Q4 report, expected around March 2027, tests whether $49–$54 million of adjusted EBITDA and an 11.05%…ORKAOruka TherapeuticsMedium Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely in 61% of high-dose patients against 0% on placebo, and the December 2026 52-week EVERLAST-A data…PARPAR TechnologyMedium PAR Technology's restaurant software is growing faster than its share price assumed: recurring revenue rose 18.1% and 2026 guidance was raised on 5 November 2026. The late-February 2027 fourth-quarter report shows whether organic growth…PCORProcore TechnologiesMedium Procore Technologies' third-quarter beat and raised 2026 outlook give the shares a modest edge over the S&P 500 even after a 29.1% three-month rise; the fourth-quarter report, expected around February 2027, settles whether growth and the…PGProcter & GambleMedium Procter & Gamble's volume-led growth restart, with organic sales up 4% last quarter, makes it modestly likelier to beat the S&P 500 while Brent near $96 stays under the $100 its cost plan assumes. The 19 November 2026 Investor Day and the…PLNTPlanet FitnessMedium Planet Fitness's third-quarter beat, raised sales outlook and five analyst target increases give the shares a modest edge over the S&P 500; flat membership of about 21.5 million means the New Year join season and the February 2027 report…PRCHPorch GroupMedium Porch Group's insurance fees beat in Q3 2026 and lifted 2026 adjusted EBITDA guidance to $135-140M, and the shares hit a 52-week high on 10 November 2026 despite CEO stock sales. Year-end Reciprocal surplus and the Q4 report around…PSIXPower Solutions InternationalMedium Power Solutions International's record third-quarter profit, raised second-half outlook and new multi-year engine supply deal support the shares beating the S&P 500. The fourth-quarter report, where management addresses 2027 data-center…PTLOPortillo'sMedium Portillo's turned same-restaurant sales positive and raised adjusted EBITDA guidance to $98–$101 million on 5 November 2026, leaving the shares modestly likelier than not to beat the S&P 500. Transactions still fell 0.7%, so the January…PUBMPubMaticMedium PubMatic's Q3 2026 beat, with revenue up 17% to $79.6 million and connected TV growth above 30%, supports a revenue recovery the shares have nearly priced back to their 52-week high; Q4 revenue of at least the $91 million guidance floor…PVLAPalvella TherapeuticsMedium Palvella Therapeutics has pulled back from its record close while the FDA reviews QTORIN rapamycin for a 28 February 2027 decision, with no adverse review news and $236.7 million in cash; review updates and the fourth-quarter Phase 3 start…RCELAvita MedicalMedium AVITA Medical's shares are modestly more likely than not to beat the S&P 500 after 53% revenue growth and a raised $92–94 million 2026 guide; the fourth-quarter report shows whether promised cash-flow breakeven arrives.RCLRoyal Caribbean GroupMedium Royal Caribbean Group's third-quarter beat, raised 2026 outlook and rising analyst targets give the shares a modestly better-than-even chance of beating the S&P 500, despite heavy director selling in November 2026. The fourth-quarter…RDVTRed VioletMedium Red Violet's identity-data business still grows faster than its costs, with third-quarter 2026 revenue up 20% and a 40% adjusted EBITDA margin, giving the shares modestly better than even odds of beating the S&P 500. The fourth-quarter…REALRealRealMedium The RealReal's 29 October 2026 beat and raise, with luxury-resale GMV up 23%, makes the shares modestly likely to beat the S&P 500; the fourth-quarter report must deliver the guided $27.5–29.0 million of adjusted EBITDA.REFReformationMedium Reformation's shares are modestly more likely than not to beat the S&P 500: revenue grows about 20% and the 2026 sales outlook was raised to $610–612 million. Holiday trading from 27 November 2026 and the estimated 26 January 2027 IPO…REGNRegeneron PharmaceuticalsMedium Regeneron's shares are modestly more likely than not to beat the S&P 500 because it now keeps its full Dupixent profit share, with EYLEA HD and Libtayo adding growth. The November 2026 cemdisiran FDA decision, the 4 December 2026 EYLEA HD…REPLReplimune GroupMedium Replimune's melanoma drug TUDRIQEV, first delivered on 6 October 2026, gives the shares a modest edge over the S&P 500 as early prescribing builds. The fiscal third-quarter report, expected around February 2027, carries the first sales…REZIResideo TechnologiesMedium Resideo Technologies is modestly more likely than not to beat the S&P 500 after a third-quarter beat in its first full quarter as a standalone controls maker. The fourth-quarter report expected in February 2027 shows whether its 6% core…RKLBRocket LabMedium Rocket Lab's record third-quarter revenue of $267.8 million and its $3.57 billion backlog give the shares a modestly better-than-even case against the S&P 500 over three months. A dated Neutron launch quarter and fourth-quarter revenue…RTXMedium RTX Corporation's record $340 billion backlog and raised 2026 guidance outweigh a defense budget now likely to slip into 2027; the 11 December 2026 funding deadline and the first 2027 guidance at the late-January report settle the case.SAROStandardAeroMedium StandardAero's engine-overhaul profits are growing faster than revenue: third-quarter 2026 adjusted EBITDA rose 15% and the company raised 2026 guidance again on 5 November 2026. The fourth-quarter report, expected around 26 February 2027,…SDGRSchrodingerMedium Schrödinger's software revenue returned to growth and its full-year contract-value guidance rose to $222–232 million, giving the shares a modest edge over the S&P 500. The fourth-quarter report, expected around late February 2027, settles…SEZLSezzleMedium Sezzle's third-quarter beat, with credit-loss provisions at 2.7% of transaction volume, 955,000 subscribers and a $7.20 2027 EPS target, gives Sezzle Inc. shares a modest edge over the S&P 500. Fourth-quarter credit, reported around late…SGSweetgreenMedium Sweetgreen's comparable sales turned positive in October, up about 5% after the cyclospora outbreak, which gives the shares a modest edge over the S&P 500. Fourth-quarter comparable sales, which management expects to grow about 4%, settle…SGHTSight SciencesMedium Sight Sciences' TearCare dry-eye treatment is becoming a second revenue line beside its OMNI glaucoma devices, giving the shares a modest edge over the S&P 500: third-quarter dry-eye sales rose 45% to $3.9 million, and UBS raised its…SHOPShopifyMedium Shopify's growth case holds after its third-quarter 2026 report, with revenue up 32% and low-thirties fourth-quarter guidance, though merchant sales growth slowed to 29%. The holiday sales tally around 1 December 2026 and the February 2027…SIBNSI-BONEMedium SI-BONE's recovery case holds after a third-quarter beat and a final 2027 Medicare office payment, giving its shares a modest edge over the S&P 500. Late-February results settle it by showing whether fourth-quarter growth topped 20%.SIGSignet JewelersMedium Signet Jewelers is earning more on flat sales after raising fiscal 2027 adjusted EPS guidance to $10.45–$12.15; its 2 December 2026 third-quarter report tests that range against an $11.70 Zacks consensus in its upper half.SLDESlide Insurance HoldingsMedium Slide Insurance is earning well ahead of plan on Florida homeowners policies and paying a $1.50 special dividend after raising 2026 net income guidance to $500–520 million. The fourth-quarter report, estimated around 25 February 2027,…SMGScotts Miracle-GroMedium Scotts Miracle-Gro's margin recovery gives the shares a modest edge: fiscal 2027 adjusted EPS guidance of $4.70 to $4.90 meets the $4.71 consensus despite about $100 million of commodity inflation. The late-January 2027 report and spring…SMMTSummit TherapeuticsMedium Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's reading of a primary survival result with p=0.057 settles it, and the shares closed at $15.07 on 12…STGWStagwellMedium Stagwell's technology and data units are lifting profit faster than revenue, with third-quarter adjusted EBITDA up 25% on 10% revenue growth, giving the shares a modest edge. The February 2027 guidance, the first without election spending,…TDOCTeladoc HealthMedium Teladoc Health's Q3 2026 beat and fast-growing BetterHelp insurance revenue give the shares a modest edge over the S&P 500. The refinancing of $1.0 billion of notes due June 2027 and the Q4 report settle whether the turnaround holds.TLNTalen EnergyMedium Talen Energy's new seven-year Ohio capacity sale and its 2027 guidance of $2.5–2.85 billion adjusted EBITDA make the shares modestly more likely than not to beat the S&P 500. PJM's December 2026 capacity auction will test whether…TMOThermo Fisher ScientificMedium Thermo Fisher Scientific's 6% third-quarter organic growth, raised 2026 outlook and $5 billion buyback give the shares a modest edge over the S&P 500. The late-January 2027 report and first 2027 guidance decide whether that growth holds.TREELendingTreeMedium LendingTree's insurance-led growth, falling debt and first planned buyback since 2022 give its shares a modest edge over the S&P 500 even after they gave back part of the post-report rally. The fourth-quarter report settles whether the…TSMTaiwan Semiconductor ManufacturingMedium Taiwan Semiconductor Manufacturing's record October sales of NT$586.89 billion put fourth-quarter revenue on pace for the top of guidance, giving the shares a modest edge over the S&P 500. Nvidia's 17 November 2026 report and TSMC's…TTEKTetra TechMedium Tetra Tech's $4.67 billion backlog, up 13%, and fiscal 2027 guidance above consensus give it a modest edge over the S&P 500. The late-January 2027 first-quarter report shows whether net revenue lands inside the $1.040–$1.080 billion…TWTradeweb MarketsMedium Tradeweb Markets' 26.3% October volume growth points to fourth-quarter revenue growth above the third quarter's 14.9%. The November volume report around 4 December 2026 and fourth-quarter results show whether revenue keeps pace as credit…TXNTexas InstrumentsMedium Texas Instruments' analog upturn, driven by data-center demand and pricing that lifted third-quarter 2026 revenue 28%, gives the shares a modest edge over the S&P 500. The late-January 2027 report, measured against the $5.80–6.30 billion…UBERUber TechnologiesMedium Uber Technologies shares are modestly more likely to beat the S&P 500: third-quarter bookings rose 20% with profit growing faster, yet the stock sits 25.7% below its high. The early-February 2027 report shows whether bookings growth holds…UFPTUFP TechnologiesMedium UFP Technologies is growing above its own target, with 11.1% Q3 2026 organic growth against a 6%–9% goal, while delayed Dominican Republic transfers hold margins back. The Q4 report, expected around March 2027, shows whether growth stays…UNHUnitedHealth GroupMedium UnitedHealth Group's earnings recovery, with 2026 adjusted EPS guided to at least $20.50 and a buyback widened by 50 million shares, gives the shares a modest edge over the S&P 500; the 7 December 2026 Medicare enrollment close and the…UPBDUpbound GroupMedium Upbound Group's tighter Acima lending is lifting profit and cash flow as lease volume shrinks, Brigit adds growth, and executives kept buying stock; the late-February 2027 Q4 report shows whether Acima volume levels off as guided.VCELVericelMedium Vericel's knee-cartilage implant MACI is growing above 20% a year and the 5 November 2026 report raised 2026 revenue guidance to $344–346 million. The fourth-quarter report settles the case by showing whether MACI reaches about $102…VEEVVeeva SystemsMedium Veeva Systems is modestly more likely than not to beat the S&P 500, after it said its fiscal third quarter would meet or exceed guidance and ten analyst firms raised targets; the 3 December 2026 report shows whether revenue clears $932–935…VEONMedium VEON raised the floor of its 2026 revenue and EBITDA growth guidance on 6 November 2026 as digital profit outgrew digital sales, backing its shift from mobile carrier to digital operator; the 16 November 2026 Capital Markets Day tests the…VERXVertexMedium Vertex's 4 November 2026 third-quarter beat, with cloud revenue up 20.4% and net revenue retention up to 106%, gives the tax-software shares a modest edge over the S&P 500; the fourth-quarter report, expected around late February 2027,…VIAVia TransportationMedium Via Transportation's shares are modestly more likely than not to beat the S&P 500, after a third-quarter beat, a raised 2026 revenue guide and five target increases; the fourth-quarter report, expected around late February 2027, settles it…VRDNViridian TherapeuticsMedium Viridian Therapeutics' shares are modestly more likely than not to beat the S&P 500: Lumvoa's $24.7 million first full quarter beat estimates and VRDN-008 data on 9 November 2026 added an autoimmune program. Fourth-quarter Lumvoa sales,…VSTVistraMedium Vistra Corp. shares lean toward beating the S&P 500 on 2027 adjusted EBITDA guidance of $7.7–8.5 billion. Texas data-center policy settles it: the December 2026 grid audit and the new governor's first moves after 19 January 2027.VYXNCR VoyixMedium NCR Voyix's shares have a modest edge over the S&P 500 because large grocers and restaurant chains are signing onto its cloud platform and its margins are rising. The fourth-quarter report, expected in February 2027, shows whether 2026…XNCRXencorMedium Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding into 2029. First-half 2027 data in at least 20 patients at 400 mcg/kg and the FDA's view on…ZLABZai LabMedium Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line response rate; a global first-line Phase 3 start announced by 31 December 2026 settles it.ZVRAZevra TherapeuticsMedium Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026 and the company is profitable; the EMA re-examination of arimoclomol, guided to the fourth quarter,…AAAlcoaMedium Alcoa Corporation is modestly more likely than not to beat the S&P 500 over three months: alumina output recovered in the third quarter and Bank of America upgraded the shares to Buy on 5 November 2026. The fourth-quarter report, expected…AAONMedium AAON, the rooftop and data-center cooling maker, is modestly more likely to lead the S&P 500 over three months: a record third quarter and raised 2026 guidance lifted the shares from a $54.42 low. The fourth-quarter report and annual…ABNBAirbnbMedium Airbnb's faster third-quarter growth, raised 2026 outlook and $12 billion buyback give its shares a modest edge over the S&P 500; fourth-quarter revenue against the $3.22–$3.28 billion guide, due around mid-February 2027, settles it.ABVXAbivax SAMedium Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative colitis marketing application to the fourth quarter of 2026; a filing by 31 December 2026 settles it.ABXAbacus Global ManagementMedium Abacus Global Management's shift to recurring fees is backed by third-quarter revenue up 22% and doubled GAAP profit, so the shares are modestly more likely than not to beat the S&P 500; the fourth-quarter report around February 2027…ACBAurora CannabisMedium Organigram Global's agreed C$7.80-per-share deal sets the value for Aurora Cannabis, whose shares trade below it; Curaleaf's response before its offer expires on 4 December 2026 and December shareholder votes settle whether holders get…ACCOAcco BrandsMedium ACCO Brands is more likely to beat the S&P 500 over three months as a debt-paydown case: it raised 2026 free cash flow guidance to about $100 million on 29 October 2026 while comparable sales fell 6.2%. The late-February 2027 report shows…ACHCAcadia HealthcareMedium Acadia Healthcare is modestly more likely than not to beat the S&P 500 over three months: on 4 November 2026 it raised fiscal 2026 adjusted EBITDA guidance to $615–625 million. The fourth-quarter results, expected in late February 2027,…ACIWACI WorldwideMedium ACI Worldwide is more likely to beat the S&P 500 over three months: third-quarter 2026 revenue hit the top of guidance and profit guidance rose. Fourth-quarter results, due around February 2027, settle it.ACLSAxcelis TechnologiesMedium Axcelis Technologies guided fourth-quarter 2026 revenue to about $275 million, far above the $238.8 million analyst estimate, which makes the shares modestly more likely than not to beat the S&P 500 over three months; gross margin and…ADIAnalog DevicesMedium Analog Devices is modestly more likely than not to beat the S&P 500 over three months on 40% industrial and AI data-center revenue growth; its 24 November 2026 report tests the $4.3 billion revenue guide.AEISAdvanced Energy IndustriesMedium Advanced Energy Industries is modestly more likely to beat the S&P 500 over three months: third-quarter revenue of $696.4 million beat its guide and fourth-quarter guidance is $735 million, yet the shares sit 42.4% below their 52-week…AGYSAgilysysMedium Agilysys's shares are modestly more likely than not to beat the S&P 500 because its hotel and casino software is moving to subscriptions faster than guided: fiscal Q2 subscription revenue rose 32.6% and FY2027 guidance was raised on 26…AIPArterisMedium Arteris, which licenses the on-chip wiring that moves data inside processors, is modestly more likely than not to beat the S&P 500 over three months: it raised 2026 revenue guidance to $98.5–99.5 million on 5 November 2026 and the shares…ALABAstera LabsMedium Astera Labs shares are modestly more likely than not to beat the S&P 500: third-quarter revenue of $584.9 million beat guidance and the $730–750 million fourth-quarter outlook tops consensus. The report expected around 10 February 2027…ALKSAlkermesMedium Alkermes plc's shares are modestly more likely to beat the S&P 500 over three months: third-quarter revenue beat guidance and the LYBALVI settlement with Teva pushes generic entry to 2039. Vibrance-3, guided to complete in the fourth…ALNTAllientMedium Allient's record third-quarter orders and margins make the shares modestly more likely than not to beat the S&P 500 over three months; whether the $351.5 million backlog turns into revenue and cash, shown in fourth-quarter results due…AMCAmc Entertainment HoldingsMedium AMC Entertainment's third quarter delivered $109.3 million of free cash flow with no rise in share count, so the shares are rated modestly likely to beat the S&P 500; Thanksgiving attendance and the fourth-quarter report show whether that…AMPAmeriprise FinancialMedium Ameriprise Financial is modestly more likely to beat the S&P 500 over three months: third-quarter earnings rose 21.7% and Huntington's advisors arrive in the fourth quarter. The fourth-quarter report, expected around 28 January 2027, tests…AMRXAmneal PharmaceuticalsMedium Amneal Pharmaceuticals is more likely than not to beat the S&P 500 over the next three months: biosimilars, specialty drugs and lanreotide drove a beat and a guidance raise on 3 November 2026. The report due around late February 2027 shows…ANDGAndersen GroupMedium Andersen Group's shares are modestly more likely to lead the S&P 500 over three months. Its 12 November 2026 report raised 2026 guidance and set 2027 revenue at $1.275–1.325 billion, above the $1.175 billion estimate. The fourth-quarter…AOSLAlpha and Omega SemiconductorMedium Alpha and Omega Semiconductor is more likely than not to beat the S&P 500 over three months: AI and server chips passed 20% of revenue and December-quarter guidance of about $180 million tops consensus. The report due around February 2027…AOUTAmerican Outdoor BrandsMedium American Outdoor Brands is more likely to lead the S&P 500 over three months on a 53.0% gross margin, raised profit guidance and a $10 million buyback; the fiscal second-quarter report, estimated for about 8 December 2026, shows how much…ARCBArcBestMedium ArcBest's Asset-Based margin gains and Asset-Light recovery make the shares modestly more likely than not to beat the S&P 500 over three months; the fourth-quarter report, estimated 28 January 2027, tests the guided margin slip and weak…ARDTArdent HealthMedium Ardent Health's cost-led hospital turnaround is running ahead of plan, with 2026 adjusted EBITDA guidance raised to $500–$535 million and Guggenheim and Stephens targets at $21; the 2027 outlook due with year-end results settles whether…ATENA10 NetworksMedium A10 Networks' third-quarter revenue rose 22.6% to $91.5 million and full-year growth guidance went to about 16%, which moves the case from unproven to supported; the shares still trade below the $30 June breakout level.ATHMAutohomeMedium Autohome's capital-return case gained support: third-quarter revenue fell 26%, a smaller drop than 32% in Q2, while buybacks reached US$155.4m and a second dividend was declared. Falling profit and the 10 November 2026 close of $22.46 keep…ATIMedium ATI Inc., the titanium and nickel-superalloy supplier to aerospace, is modestly more likely than not to beat the S&P 500: its 12 November 2026 Investor Day set 2029 targets well above 2026, and the fourth-quarter report tests whether…ATRCAtriCureMedium AtriCure's 3 November 2026 report backed its profit-led re-rating with 15.0% revenue growth and adjusted EPS guidance raised to $0.40–$0.46, so the shares modestly favour beating the S&P 500. The fourth-quarter report in early 2027 decides…AVAHAveanna Healthcare HoldingsMedium Aveanna Healthcare's shares are modestly more likely than not to beat the S&P 500 over three months: on 12 November 2026 it beat estimates and raised its 2026 outlook, yet the shares fell to $12.24. The fourth-quarter report in early 2027…AXTIAXTMedium AXT, Inc.'s indium-phosphide substrate demand (record $73.41M quarter, about $90M guided for Q4) favors the shares over three months; Q4 shipments and Lumentum's orders after the Marvell deal settle it.BFLYButterfly NetworkMedium Butterfly Network's chip-licensing business beat guidance in the third quarter, and the shares are modestly more likely than not to beat the S&P 500 over three months; the fourth-quarter report, expected around late February 2027, settles…BHVNBiohavenMedium Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over three months: the SK Biopharmaceuticals licence has cleared US antitrust, and receipt of its $350 million payment plus the second-half 2026 RISE3 epilepsy readout…BILLBILL HoldingsMedium BILL Holdings' profit growth now outweighs its shrinking customer count: fiscal first-quarter 2027 non-GAAP operating income was $136.9 million and guidance rose, but businesses served fell to 475,300. The fiscal second-quarter report…BKSYBlackSky TechnologyMedium BlackSky's Q3 revenue of $42.8M (+118%) and a raised FY2026 guide of $140M–$150M strengthen the recovery case; Gen-3 launch timing and equity issuance settle how much the price keeps, with Investor Day on 2 December 2026.BLLNBillionToOneMedium BillionToOne is more likely to beat the S&P 500 over three months: it beat and raised on 4 November 2026 (revenue $123.0 million, up 47%) and is profitable with $561.5 million in cash. The fourth-quarter report, expected around March 2027,…BLZEBackblazeMedium Backblaze's cloud-storage business is accelerating: the 2 November 2026 report beat guidance and raised the 2026 outlook, yet the shares remain far below August on CoreWeave credit fears. Revenue from CoreWeave's ramp in Q4 2026 settles it.BMYBristol-Myers SquibbMedium Bristol Myers Squibb raised 2026 revenue guidance to $49.75–$50.25 billion on 29 October 2026 but cut adjusted EPS guidance to $6.35–$6.55 on licensing charges; the early-2027 report shows whether earnings power follows revenue.BRKRBrukerMedium Bruker Corporation's 4 November 2026 third-quarter report lifted margin and cash flow, but organic revenue grew only 0.7% and sales guidance was cut again; the early-February 2027 report decides whether growth accelerates.BTCSMedium BTCS Inc.'s decentralized-finance unit doubled gross profit to a record $3.5 million in the third quarter of 2026, which keeps the shares modestly more likely to beat the S&P 500 over three months; $27.0 million of new borrowing and…CACICACI InternationalMedium CACI International is more likely to beat the S&P 500 over three months: fiscal 2027 guidance was raised on 21 October 2026 and funded backlog grew 14.8%. The next report (~27 January 2027, est.) settles it: organic growth must top 2.1%…CAKECheesecake FactoryMedium The Cheesecake Factory's flagship traffic rose 9.5% last quarter and management raised 2026 and 2027 sales guidance, yet the shares closed at $109.67 on 11 November 2026, below their October high. The fiscal Q4 report, expected around…CARGCarGurusMedium CarGurus' third-quarter report on 5 November 2026 landed at the top of guidance and added a $250 million buyback, but fourth-quarter guidance implies slower growth and a New York City lawsuit is open; the fourth-quarter report settles it.CBLLCeriBellMedium CeriBell's delirium monitor, launched 2 November 2026, should add headband usage to a seizure-monitoring business growing 30%, so the shares are modestly more likely to beat the S&P 500 over three months; 2027 guidance with the…CCLCarnivalMedium Carnival's record 2027 bookings, investment-grade balance sheet and a retreat in crude oil make the shares modestly more likely to beat the S&P 500 over three months; the fourth-quarter report, expected around 18 December 2026, settles it.CDWMedium CDW Corporation is modestly more likely to beat the S&P 500 over three months: AI server sales lifted third-quarter gross profit 10% and margin recovered to 20.5%. The fourth-quarter report, expected around February 2027, settles whether…CECOCECO EnvironmentalMedium CECO Environmental's third-quarter report showed orders of $777.6 million, backlog of $2,193.5 million and a raised 2026 free cash flow target; the next report decides whether the 2027 outlook of $2.1–$2.3 billion revenue holds.CLDTChatham Lodging TrustMedium Chatham Lodging Trust's raised 2026 earnings outlook, driven by Silicon Valley business travel, gives its shares a modest edge over the S&P 500. First 2027 guidance, expected around late February 2027, shows whether the gains outlast easy…CLOVClover Health InvestmentsMedium Clover Health's profit is rising with Medicare Advantage membership, and the 4 November 2026 quarter lifted full-year guidance; the CMS appeal of the court-ordered Star Rating remains the event that can reverse the gains.CLYMClimb BioMedium Climb Bio's budoprutug showed a clear antibody effect in membranous nephropathy and the third-quarter report kept funding into the second half of 2028; the December 2026 ASH immune thrombocytopenia data test whether the drug works beyond…CMECME GroupMedium CME Group is more likely to beat the S&P 500 over three months: record October volume of 30 million contracts a day followed record third-quarter revenue. The November volume release, expected around 2 December 2026, shows whether activity…CMGChipotle Mexican GrillMedium Chipotle Mexican Grill's customer traffic is growing again (third-quarter transactions +0.8%, comparable sales +2.1%), which modestly favors the shares over the S&P 500; the fourth-quarter report in early 2027 settles whether margins stop…CMPSCOMPASS PathwaysMedium Compass Pathways is modestly more likely to beat the S&P 500 over three months: its COMP360 psilocybin filing was completed on 9 November 2026 under a one-to-two-month voucher review target, and FDA acceptance and an action date decide…CNCCenteneMedium Centene is more likely to beat the S&P 500 over three months: its raised 2026 adjusted EPS guidance of more than $5.20 shows medical costs improving. The fourth-quarter report, expected in February 2027, settles whether it holds.CODICompass DiversifiedMedium Compass Diversified is cutting debt faster than its earnings are shrinking: covenant leverage fell to about 4.5 times at 30 September 2026 and the 2026 outlook floor rose to $330 million. Another subsidiary sale or an outlook cut settles…COHRCoherentMedium Coherent's raised guidance, a roughly $20 billion PhotonLink laser agreement and open-market buying by its CEO support shares still 46.7% below their June high. The fiscal Q2 report against the $2.55–2.75 billion revenue guide settles the…CORTCorcept TherapeuticsMedium Corcept Therapeutics' Lifyorli launch is compounding ($91.4 million in Q3 2026, up from $47.6 million in Q2), yet the shares sit near their 200-day average on an unchanged $1.1–$1.2 billion revenue guide; the 17 December 2026 FDA decision…CRCTCricutMedium Cricut's machine sales are growing again, making its shares modestly more likely to beat the S&P 500 over three months; the fourth-quarter 2026 report, expected around early March 2027, shows whether holiday demand held without one-time…CTOSCustom Truck One SourceMedium Custom Truck One Source's rental fleet growth and a third 2026 Adjusted EBITDA guidance raise, to $447.5–$460 million, make a modest lead over the S&P 500 more likely; Q4 truck deliveries and year-end leverage settle it.CVLGCovenant Logistics GroupMedium Covenant Logistics' adjusted operating ratio improved to 95.0% in Q3 2026 from 95.9% in Q2, which leaves the shares modestly more likely than not to beat the S&P 500; the Q4 report, expected around 28 January 2027, settles whether the gain…DIODDiodesMedium Diodes Incorporated is more likely to lead the S&P 500 over three months: third-quarter revenue rose 35.8% and the company guided the fourth quarter to about $550 million. The fourth-quarter report, expected around mid-February 2027,…DOCNDigitalOcean HoldingsMedium DigitalOcean's AI cloud revenue beat guidance in the third quarter ($321 million, up 40%) and the year was raised, but a $1 billion stock-sale program caps the case; the fourth-quarter report decides whether growth outruns new shares.DRDDRDGOLDMedium DRDGOLD, a debt-free South African gold tailings retreater, is modestly more likely to beat the S&P 500 over three months on a 42% rise in quarterly operating profit; the regional tailings facility review ending about 14 December 2026…DTDynatraceMedium Dynatrace is modestly more likely than not to beat the S&P 500 over three months: it raised fiscal 2027 revenue and recurring-revenue guidance and added a $1 billion buyback, yet the shares fell about a third. The 16 February 2027 investor…DVADaVitaMedium DaVita is modestly more likely than not to beat the S&P 500 over three months: the third-quarter beat lifted 2026 adjusted EPS guidance to $14.30–$15.20, though shares fell to $174.07 on 12 November 2026. The February 2027 fourth-quarter…ELVNEnliven TherapeuticsMedium Enliven Therapeutics is modestly more likely than not to beat the S&P 500 over three months: $884.4 million in cash and FDA alignment fund ENABLE-2, its pivotal leukemia trial, and a disclosed first patient before year-end 2026 would…ELVRElevra LithiumMedium Elevra Lithium's September-quarter report showed sales above production, lower unit costs and the Ewoyaa sale closed, and the shares have bounced to $27.85 from a $21.96 closing low; the December-quarter report decides whether the recovery…ENTGEntegrisMedium Entegris has modestly better than even odds of beating the S&P 500: third-quarter sales and fourth-quarter guidance beat consensus, and its 9 November 2026 Investor Day set 35% operating-margin targets. The fourth-quarter report, expected…EVGOMedium EVgo's shares track majority owner LS Power's $2.00-per-share cash take-private offer and closed at $1.75 on 12 November 2026, below it. The special committee's answer settles the case: a signed deal at $2.00 closes the gap, while a…EWTXEdgewise TherapeuticsMedium Edgewise Therapeutics is modestly more likely than not to beat the S&P 500 over three months: FDA-cleared Phase 3 plans for heart drug EDG-7500, $1.74 billion of cash and unconfirmed takeover reports support it. The STRATUS-HCM trial…EXLSExlService HoldingsMedium ExlService Holdings' data-and-AI revenue lifted its 2026 organic growth guide to 15%, and the shares are modestly more likely than not to beat the S&P 500 over three months; fourth-quarter results, expected around late February 2027,…EXTRExtreme NetworksMedium Extreme Networks pairs a beat-and-raise operating quarter with a Reuters-reported sale process; a named bidder or offer settles the takeover case, and second-quarter fiscal 2027 revenue against the $345.8–350.8 million guide settles the…FAFirst AdvantageMedium First Advantage's raised 2026 guidance (revenue $1.72–1.745 billion) makes the shares modestly more likely to beat the S&P 500 over three months, but Silver Lake's $21.80 secondary on 10 November 2026 caps them; the next quarterly report…FBIZFirst Business Financial ServicesMedium First Business Financial Services is modestly more likely to beat the S&P 500 over three months on a 3.80% third-quarter margin and record earnings; fourth-quarter results in late January 2027 show if the margin and credit hold.FLEXMedium Flex Ltd. beat guidance and raised its fiscal 2027 outlook, and its Axiom spin-off stayed on track at the 10 November 2026 Innovation Day, yet the shares closed at $78.97 on 11 November 2026; the late-January 2027 third-quarter report…FLYWFlywire Corporation VotingMedium Flywire is modestly more likely than not to beat the S&P 500 over three months: third-quarter growth of 26.0% topped its 16–22% outlook and 2026 guidance rose to 25–27%. The fourth-quarter report, expected around late February 2027, tests…FNFabrinetMedium Fabrinet, which assembles optical parts for AI data centers, is modestly more likely than not to beat the S&P 500 over three months: revenue grew 51% and guidance rose, but the fiscal second-quarter report in early 2027 shows whether cash…FNKOFunkoMedium Funko's third-quarter report on 5 November 2026 beat guidance, with gross margin of 45.2% versus 43–44% and adjusted EBITDA of $32.1 million; the holiday quarter and a shrinking Loungefly line decide whether the margin gain lasts.FOSLFossil GroupMedium Fossil Group's turnaround passed its Q3 test with 59.8% gross margin and a raised fiscal 2026 outlook, so the shares are modestly more likely than not to beat the S&P 500; holiday sales and year-end free cash flow settle it.FROGJFrogMedium JFrog's third-quarter beat and second full-year raise, with cloud revenue up 60%, support the shares leading the S&P 500. The fourth-quarter report, due around February 2027, tests whether revenue meets the $183M-$185M guide.FWRDForward AirMedium Forward Air Corporation's debt burden is falling on rising earnings: net leverage dropped to 4.7 times at 30 September 2026 from 5.2 times in June, making the shares modestly likely to beat the S&P 500. The next leverage report shows…GGenpactMedium Genpact's technology unit is growing fast enough to lift the company, so the shares are more likely than not to beat the S&P 500 over three months; the February 2027 fourth-quarter report shows whether ATS growth holds above 25%.GCMGGCM GrosvenorMedium GCM Grosvenor is modestly more likely to beat the S&P 500 over three months: third-quarter fee-related earnings rose 15% and fundraising reached $2.7 billion. The fourth-quarter report, expected around February 2027, shows whether 2026…GCTGigaCloud TechnologyMedium GigaCloud Technology's marketplace is growing faster than guided, so the shares are modestly more likely to lead the S&P 500 over three months; the fourth-quarter report, estimated for late February 2027, shows if revenue meets the $425…GENIGenius SportsMedium Genius Sports' official sports data business beat third-quarter revenue and raised 2026 guidance on 5 November 2026, so the shares are modestly more likely to lead the S&P 500 over three months; the fourth-quarter report, expected around…GEOGEO GroupMedium The GEO Group is modestly more likely to beat the S&P 500 over three months: third-quarter revenue rose 12% on 5 November 2026, profit guidance went up and two 10-year ICE contracts began. Federal funding when the stopgap spending bill…GFSGlobalFoundriesMedium GlobalFoundries, a contract chipmaker, delivered the AI growth it guided in its 4 November 2026 third-quarter report, yet the shares fell to $40.62 on a roughly $4 billion 2027 spending plan and more dilution. Fourth-quarter revenue…GRNDGrindrMedium Grindr beat and raised on 5 November 2026 and gave a 2027 revenue outlook of at least $705 million, but slowing user growth and a thinner margin kept the shares near $13.47; the 17 November 2026 Edge launch and the Q4 report decide it.GTNGray MediaMedium Gray Media's record political quarter and a $175–200 million Q4 debt-reduction target make the shares modestly more likely than not to beat the S&P 500; the Q4 report and 2027 outlook, due around 27 February 2027, settle whether the cash…HAFNHafniaMedium Hafnia Limited's shares are modestly more likely to beat the S&P 500 over three months because peers report fourth-quarter product tanker bookings far above Hafnia's $30,716 per day for the third quarter; the 18 November 2026 report shows…HNIMedium The Steelcase merger is lifting HNI Corporation's earnings faster than its sales: third-quarter adjusted EPS of $1.62 beat the $1.40 consensus, so the shares are slightly more likely than not to beat the S&P 500. The late-February 2027…HPHelmerich & PayneMedium Helmerich & Payne is modestly more likely than not to beat the S&P 500 over three months, resting on its 7 October 2026 guide to high-end fiscal fourth-quarter margins; the 19 November 2026 results call settles it through adjusted profit…HRBH&R BlockMedium H&R Block is more likely than not to beat the S&P 500 over three months: management reaffirmed fiscal 2027 adjusted EPS of $6.04–$6.24 on 9 November 2026; the 3 December 2026 Investor Day is next, and the filing season settles it.HURNHuron Consulting GroupMedium Huron Consulting's adjusted earnings are growing faster than revenue and buybacks are retiring about 10% of shares, so the shares are modestly more likely than not to beat the S&P 500; fourth-quarter organic growth settles it.IAGIAMGoldMedium IAMGOLD is modestly more likely than not to beat the S&P 500 over three months on large cash flow and a net cash balance, but gold's fall after hot US inflation data weighs on it; the Fed's 9 December 2026 decision and the December royalty…IMVTImmunovantMedium Immunovant's 9 November 2026 rheumatoid arthritis win at the 600 mg dose of IMVT-1402 makes the shares modestly more likely than not to beat the S&P 500 over three months; FDA feedback on a registrational path, guided for late 2026 or…INNVInnovAge HoldingMedium InnovAge's earnings recovery gives the shares a modest edge over the S&P 500 over three months, but private-equity selling at $9.25 caps the move; the second-quarter fiscal 2027 report, expected around February 2027, tests whether the…IPARInterparfumsMedium Interparfums' third-quarter operating margin rose to 27.4% on flat $430 million sales and full-year sales guidance was raised to $1.490 billion; the 2027 outlook due 18 November 2026 shows whether the profit gain carries forward.IRWDIronwood PharmaceuticalsMedium Ironwood Pharmaceuticals is modestly more likely to beat the S&P 500 over three months: it raised 2026 guidance twice and cut debt, but the 2027 LINZESS price cut makes initial 2027 guidance, expected around 5 January 2027, the test.JAKKJAKKS PacificMedium JAKKS Pacific's licensed Disney doll, role-play and costume lines lifted third-quarter sales 20% and net income 50%, and the shares are modestly more likely than not to beat the S&P 500 over three months. Black Friday on 27 November 2026…JBIOJade BiosciencesMedium Jade Biosciences' IgA nephropathy antibody JADE101 is funded into the fourth quarter of 2028, which leaves the shares modestly likelier than not to beat the S&P 500 over three months; the EVERGREEN Phase 3 start guided for the fourth…JRSHJerash Holdings (US)Medium Jerash Holdings beat its fiscal Q2 guidance on 10 November 2026 and guided fiscal Q3 revenue to $49–51 million against a $44.6 million consensus, with plants fully booked through June 2027. The fiscal Q3 report due around 10 February 2027…KAROKaroooooMedium Karooooo's record quarterly operating profit and 18% subscriber growth make the shares modestly more likely than not to beat the S&P 500 over three months; the third-quarter fiscal 2027 report, estimated for about 19 January 2027, shows…KFRCKforceMedium Kforce's technology-staffing recovery should lead the S&P 500 over the next three months after third-quarter revenue of $357.8 million beat guidance; fourth-quarter revenue against the $352–360 million guide, due around early February…KLACKLAMedium KLA Corporation's shares are modestly more likely to beat the S&P 500 over three months, as its raised outlook and Applied Materials' 12 November 2026 beat show chip-tool demand holding. KLA's December-quarter report, expected around 28…KMTSKestra Medical TechnologiesMedium Kestra Medical Technologies is modestly more likely than not to beat the S&P 500 over three months: revenue grew 60% and gross margin reached 56.5%. The fiscal second-quarter report, estimated for about 10 December 2026, tests the $141…LGNLegenceMedium Legence Corporation's third-quarter beat, raised 2026 outlook, first 2027 outlook and $150 million buyback make the shares modestly more likely than not to beat the S&P 500 over three months; the fourth-quarter report, expected around…LGNDLigand PharmaceuticalsMedium Ligand Pharmaceuticals is more likely than not to beat the S&P 500 over three months: royalty revenue rose 51% to $70.3 million in the third quarter, and the 8 December 2026 Investor Day shows whether the five-year outlook and 2027 XOMA…LILAKLiberty Latin AmericaMedium Liberty Latin America's wider margins, lower leverage and over $150 million of buybacks make its shares modestly more likely than not to beat the S&P 500 over three months; rebased revenue fell 2%, so the fourth-quarter 2026 report, due…LRMRLarimar TherapeuticsMedium Larimar Therapeutics is modestly more likely than not to lead the S&P 500 over three months: it finished its nomlabofusp filing on 9 November 2026 and seven insiders bought shares on 11 November 2026 and 12 November 2026. The FDA's filing…LTHLife Time Group HoldingsMedium Life Time Group Holdings' 29 October 2026 third-quarter beat and raised 8.5%–8.7% comparable-center revenue outlook support a modest lead over the S&P 500; the fourth-quarter report and six club openings settle it.LYELLyell ImmunopharmaMedium Lyell Immunopharma's ronde-cel is posting response rates strong enough to support a planned 2027 approval filing, with a 91% response rate in 44 pivotal-trial patients and funding into 2028. The December 2026 ASH presentations are the next…MBXMBX BiosciencesMedium MBX Biosciences is modestly more likely than not to beat the S&P 500 over three months: $481.6 million of cash funds canvuparatide into 2029, and the 12-week MBX-4291 obesity data guided for the fourth quarter of 2026 settle the second…MCSMarcusMedium The Marcus Corporation's shares are modestly more likely to beat the S&P 500 over three months, because theatre attendance rose 16.8% in the fiscal third quarter; the 18 December 2026 Avengers: Doomsday release and the late-February fiscal…MEDPMedpace HoldingsMedium Medpace, the clinical research contractor, is modestly more likely to beat the S&P 500 over three months: third-quarter awards of $873.4 million and a raised 2026 earnings outlook support it. The February 2027 fourth-quarter report settles…MIRMMirum PharmaceuticalsMedium Mirum Pharmaceuticals is modestly more likely than not to lead the S&P 500 over three months: both Phase 3 hepatitis delta studies are positive and LIVMARLI sales are growing. The report expected around 25 February 2027 tests the $715–720…MKSIMKSMedium MKS Inc. is modestly more likely than not to beat the S&P 500 over three months: third-quarter revenue of $1.413 billion rose 43.0% from a year earlier and the fourth-quarter guide is $1.490 billion. The fourth-quarter report, expected…MNKDMannKindMedium MannKind's Furoscix and royalty pivot makes the shares modestly more likely to beat the S&P 500 over three months; the fourth-quarter report, expected around March 2027, tests management's goal of fourth-quarter Furoscix sales above the…MPWRMonolithic Power SystemsMedium Monolithic Power Systems' AI server power-chip sales are running ahead of expectations after a Q3 beat and a Q4 guide above consensus, and the shares have recovered from the 5 November 2026 chip sell-off. The Q4 report, expected in early…MRCYMercury SystemsMedium Mercury Systems beat fiscal first-quarter 2027 forecasts and raised its profit and cash outlook on 10 November 2026, giving the shares a modest edge over the S&P 500. The fiscal second-quarter report shows whether margins and cash keep…MTRNMaterionMedium Materion's record backlog (up about 35% from a year earlier) and raised $7.10–$7.40 earnings guidance make the shares modestly more likely to beat the S&P 500 over three months; the fourth-quarter report, estimated for 24 February 2027,…MURMurphy OilMedium Murphy Oil is modestly more likely to beat the S&P 500 over three months: third-quarter output of 186,495 boe/d beat guidance, but Brent's drop to $92.57 on 9 November 2026 makes crude prices and fourth-quarter delivery the test.MYRGMYR GroupMedium MYR Group, the electrical contractor, is modestly more likely than not to beat the S&P 500 over three months: record backlog of $3.68 billion and higher margins support it. The fourth-quarter 2026 report, expected in late February 2027,…NCLHNorwegian Cruise Line HoldingsMedium Norwegian Cruise Line Holdings beat third-quarter guidance and raised its 2026 outlook on 29 October 2026, with 2027 net yield guided up 1% to 2%; first-half 2027 bookings, still behind last year, decide whether that holds.NETCloudflareMedium Cloudflare's 39% third-quarter revenue growth and raised 2026 revenue guide make its shares modestly more likely than not to beat the S&P 500, but gross margin fell to 72.4%; the fourth-quarter report, expected in early February 2027,…NPNeptune Insurance HoldingsMedium Neptune Insurance Holdings is modestly more likely than not to beat the S&P 500 over three months: third-quarter revenue grew 34.3% against a guide of about 17% for 2027, though executives keep selling. The fourth-quarter report, expected…NSPInsperityMedium Insperity's margin recovery gained support on 29 October 2026, when it lifted the floor of 2026 adjusted EBITDA guidance to $194 million; a fourth-quarter outlook below analyst estimates and $420 million of borrowings keep the case open…NXTNextpowerMedium Nextpower beat and raised fiscal 2027 guidance to $4.2B–$4.45B revenue on 28 October 2026, and the shares closed at $104.89 on 9 November 2026; the 16 November 2026 Capital Markets Day shows whether the longer-term outlook supports the…ONON SemiconductorMedium ON Semiconductor (onsemi) is modestly more likely to beat the S&P 500 because its AI data-center power revenue rose 175% to $180 million in the third quarter. The early-February 2027 fourth-quarter report, against a $1.715–$1.815 billion…ONCBeOne MedicinesMedium BeOne Medicines' BRUKINSA growth and widening margins make the shares modestly more likely to beat the S&P 500 over three months; full MANGROVE lymphoma results on 13 December 2026 test the next label, and the fourth-quarter report settles…ONTOOnto InnovationMedium Onto Innovation's shares are modestly more likely to beat the S&P 500 now that third-quarter revenue of $409.7 million topped guidance and backlog passed $1.3 billion. The fourth-quarter report, measured against a $430–450 million revenue…OPIOffice Properties Income TrustMedium Office Properties Income Trust's recovery case improved: its 9 November 2026 quarterly report confirmed full repayment of the revolver and term loan; closing of $134.1 million of pending property sales decides whether debt keeps falling.OSCROscar HealthMedium Oscar Health is modestly likely to beat the S&P 500: it raised 2026 earnings-from-operations guidance to $850–950 million on 5 November 2026 and is expanding for 2027. Open-enrollment results and the fourth-quarter report settle it.OUSTOusterMedium Ouster's lidar sales grew 50% in the third quarter to $59.3 million, above its guidance ceiling, so the shares are modestly more likely than not to beat the S&P 500 over three months. The fourth-quarter report, expected in late February…OWLBlue Owl CapitalMedium Blue Owl Capital's fee earnings grew through the private-credit withdrawal stress, so the shares are modestly more likely to beat the S&P 500 over three months; the fourth-quarter report, expected in early February 2027, settles whether…PANLPangaea Logistics SolutionsMedium Pangaea Logistics Solutions' dry-bulk earnings recovery is now in the share price, which closed at $9.46 on 12 November 2026; the shares are modestly more likely than not to beat the S&P 500 if fourth-quarter freight rates hold near the…PARRPar Pacific HoldingsMedium Par Pacific's refining earnings beat in Q3 2026 (adjusted EPS $10.70 vs $6.65 consensus) and the October refining index of $41.34 per barrel is above July's $31.34, yet the shares fell to $68.61; Q4 capture and Laramie cash settle it.PAYCPaycom SoftwareMedium Paycom Software beat Q3 estimates and raised 2026 adjusted EBITDA guidance to $1.069–1.079 billion, yet the shares closed at $237.96 on 10 November 2026 pricing a slower Q4; the early-2027 report settles whether recurring growth holds near…PCTYPaylocity HoldingMedium Paylocity's first-quarter beat and raised fiscal 2027 outlook leave the shares modestly more likely than not to beat the S&P 500 over three months; the second-quarter report, expected around February 2027, settles whether recurring revenue…PENNPENN EntertainmentMedium PENN Entertainment's digital turnaround cleared its test: the Q3 2026 report narrowed the interactive loss and kept the Q4 profit target, and the shares closed at $18.45 on 10 November 2026. The Q4 report in early 2027 decides whether…PESIPerma-Fix Environmental ServicesMedium Perma-Fix Environmental Services met the revenue test in its 5 November 2026 report, with $17.948 million against $12.885 million in Q2, but treatment still lost money and going-concern doubt remains. The first Hanford task order decides…PGNYProgynyMedium Progyny's record 1.3 million new covered lives and raised 2026 outlook keep the shares modestly more likely than not to beat the S&P 500 over three months, though they trade above the $35.33 average analyst target; the first 2027 guidance,…PIImpinjMedium Impinj's third-quarter report confirmed the RFID recovery: record revenue of $112.1M and a fourth-quarter revenue guide above consensus. Margins are guided lower, so the next report, expected in late February 2027, decides whether profit…PIIPolarisMedium Polaris Inc. is modestly more likely than not to beat the S&P 500 over three months on market-share gains and falling debt; the fourth-quarter report expected in late January 2027 shows whether retail and earnings excluding tariff refunds…PKPark Hotels & ResortsMedium Park Hotels & Resorts is modestly more likely than not to beat the S&P 500 over three months: demand is outrunning about $30 million a year of extra interest cost. The fourth-quarter report and first 2027 guidance, expected around 19…PKOHPark-Ohio HoldingsMedium Park-Ohio raised 2026 adjusted earnings guidance to $3.35–$3.50 per share after record third-quarter sales of $458.5 million, but equipment backlog slipped to $242 million; the fourth-quarter cash flow report decides whether the earnings…PLSEPulse BiosciencesMedium Pulse Biosciences is modestly more likely to lead the S&P 500 because $189.2 million of cash funds its atrial-fibrillation catheter through pivotal follow-up. The persistent-AF study filing guided for the fourth quarter of 2026 and…PMTSCPI Card GroupMedium CPI Card Group is more likely to beat the S&P 500 over three months: card-manufacturing cash is cutting its 10% debt, and 2026 free cash flow is guided to $50–55 million. The fourth-quarter report, expected around early March 2027, settles…PRMPerimeter SolutionsMedium Perimeter Group (formerly Perimeter Solutions) is modestly more likely than not to beat the S&P 500 over three months: Fire Safety profit grew 14% in the third quarter. The fourth-quarter report, expected around 26 February 2027, tests it.PTGXProtagonist TherapeuticsMedium Protagonist Therapeutics is modestly more likely than not to beat the S&P 500 over three months: it holds $834.6 million of cash and earns royalties on two approved partner drugs. J&J's January 2027 report and Protagonist's February 2027…PTRNPattern GroupMedium Pattern Group beat Q3 revenue guidance and raised 2026 revenue guidance to $3.50–3.52 billion, strengthening its ecommerce growth case; the $965–985 million Q4 guide and falling Amazon dependence decide whether the recovery holds.PYPLPayPal HoldingsMedium PayPal's cost cuts and buybacks, which lifted its 2026 adjusted EPS outlook to about $5.60, leave the shares modestly more likely to beat the S&P 500 over three months; the fourth-quarter report around 2 February 2027 settles it.QTWOQ2 HoldingsMedium Q2 Holdings' digital-banking software recovery makes the shares modestly more likely than not to beat the S&P 500 over three months, after a third-quarter beat and a raised 2026 outlook; the fourth-quarter report, expected around February…QUITAchieve Life SciencesMedium AchieveRx (formerly Achieve Life Sciences) is modestly more likely than not to beat the S&P 500 over three months if its cytisinicline resubmission to the FDA lands in the fourth quarter of 2026; the refiling, due by about 31 December…RELLRichardson ElectronicsMedium Richardson Electronics is turning a record $184.4 million backlog into 18.9% sales growth and wider margins, and the shares recovered to $19.43 after an unexplained 15.44% drop. The fiscal Q2 report, expected around 7 January 2027, shows…RELYRemitly GlobalMedium Remitly Global's Q3 adjusted EBITDA of $120.8M beat its $92–94M guide and full-year guidance rose, so the shares are modestly more likely than not to beat the S&P 500; the Q4 report settles whether margins hold.RHIRobert HalfMedium Robert Half's staffing recovery makes the shares modestly more likely than not to beat the S&P 500 over three months; the fourth-quarter report, due around late January 2027, decides it, since earnings guidance of $0.36–$0.46 sits below…RIOTRiot PlatformsMedium Riot Platforms now has a signed 910 MW Corsicana lease worth about $28 billion on top of Rockdale and AMD, so the shares are modestly more likely than not to beat the S&P 500; permanent project debt ahead of the Morgan Stanley bridge's 31…RIVNRivian AutomotiveMedium Rivian Automotive is modestly more likely than not to beat the S&P 500 over three months: R2 volume and raised guidance support the case, and the Q4 report, expected in February 2027, settles whether automotive gross margin turns positive.…RLAYRelay TherapeuticsMedium Relay Therapeutics' value rests on zovegalisib, and its 4 November 2026 quarterly report moved the case forward: $848.6 million of cash funds operations into 2029, and breast-cancer trial enrollment is guided to finish in mid-2027. The 14…RRGBRed Robin Gourmet BurgersMedium Red Robin Gourmet Burgers is more likely to beat the S&P 500 over three months: refranchising cut its debt and preliminary third-quarter comparable revenue rose 3.9%; the delayed 18 November 2026 report shows whether debt, earnings and…RSKDRiskifiedMedium Riskified's third-quarter beat and third guidance raise make its shares modestly more likely than not to beat the S&P 500: revenue rose 41% to $115.2 million and 2026 guidance rose to $427–433 million. Gross margin, down to 43% from 50%,…RVTYRevvityMedium Revvity's third-quarter report put Life Sciences back in growth (+9% pro forma organic) and lifted full-year guidance, which makes the shares modestly more likely than not to beat the S&P 500. The 13 November 2026 Investor Day tests…RZLTRezoluteMedium Rezolute's ersodetug rests on the tumor hyperinsulinism upLIFT study, with topline guided to mid-December 2026; the final responder rate against the 7-of-8 interim settles it, and a $400 million registration filed 5 November 2026 raises…SABRSabreMedium Sabre Corporation beat its Q3 EBITDA guide ($170M vs ~$155M) and raised 2026 guidance to ~$610M, but air bookings fell 1%; the 17 November 2026 Investor Day tests whether a volume-growth path exists.SAILSailPointMedium SailPoint's identity-security software is pitched by analysts as the control layer for AI agents, but reported revenue has not confirmed it; shares closed at $19.96 on 10 November 2026 and the fiscal Q3 report, expected around 9 December…SANMSanminaMedium Sanmina's AI-rack business, built on the ZT Systems purchase, is more likely than not to lead the S&P 500 over three months after a quarter that beat guidance; the fiscal first-quarter report, expected around 26 January 2027, shows whether…SAPMedium SAP SE is modestly more likely than not to beat the S&P 500 over three months: cloud backlog beat forecasts, 2026 cloud guidance moved up and JPMorgan upgraded it on 9 November 2026. The late-January 2027 report settles it.SEISolaris Energy InfrastructureMedium Solaris Energy Infrastructure is modestly more likely than not to beat the S&P 500 over three months: it beat third-quarter guidance, raised its ranges and signed a 900-megawatt contract. Fourth-quarter results, expected about 24 February…SENSSenseonics HoldingsMedium Senseonics' third-quarter revenue beat and second 2026 guidance raise give the shares a modestly better-than-even case to beat the S&P 500; the fourth-quarter iLet launch and the full-year report, which must deliver the $68–70 million…SGMTSagimet BiosciencesMedium Sagimet Biosciences' acne drug denifanstat is in a US Phase 3 trial, and the company guides that cash funds operations through mid-2029, giving the shares a modest edge over the S&P 500. AURORA enrollment and the second-half 2027 topline…SHIPSeanergy Maritime HoldingsMedium Seanergy Maritime's Capesize earnings are running ahead of its own estimate, so the shares are modestly more likely than not to beat the S&P 500 over three months; Capesize rates and the fourth-quarter report, expected around 17 February…SILCSilicomMedium Silicom's third-quarter report beat its own guide, returned the company to non-GAAP profit and lifted full-year revenue guidance to $96–98 million, yet the shares closed at $30.15 on 9 November 2026; the fourth-quarter report decides…SIMOSilicon Motion TechnologyMedium Silicon Motion's enterprise-controller ramp cleared its test: third-quarter 2026 revenue of $560.2 million beat the $519–541 million guide, yet the shares fell with memory stocks. Fourth-quarter revenue of $588–616 million decides whether…SITMSiTimeMedium SiTime Corporation's timing chips for AI datacenters beat Q3 2026 expectations with $298.7 million of revenue and guided Q4 to $331-341 million, yet the shares closed at $444.45 on 10 November 2026; Q4 results decide whether growth outruns…SMRTSmartRentMedium SmartRent's third-quarter results on 4 November 2026 showed a 41.2% gross margin and a fourth straight positive adjusted EBITDA quarter, so the shares are modestly more likely to lead the S&P 500 over three months; the fourth-quarter…SONOSonosMedium Sonos beat fourth-quarter forecasts and guided holiday revenue above consensus, so its shares are modestly more likely than not to beat the S&P 500; the early-2027 first-quarter report shows whether growth outruns memory-chip costs.SRADSportradar GroupMedium Sportradar Group AG is modestly more likely than not to beat the S&P 500 over three months, backed by third-quarter revenue up 24% and US revenue up 47%; fourth-quarter results and the Atrium Sports sale closing settle whether the shares…STMSTMicroelectronicsMedium STMicroelectronics beat its third-quarter revenue and gross-margin guidance on 29 October 2026 and guided the fourth quarter higher, but the shares ($44.70 on 10 November 2026) have fallen; the late-January fourth-quarter report decides…STRLSterling InfrastructureMedium Sterling Infrastructure is modestly more likely to beat the S&P 500 over three months: it raised 2026 adjusted EPS guidance to $21.70–21.96 and trades at a lower multiple after a 47.7% fall. Nvidia's 17 November 2026 report and the…SXCSuncoke EnergyMedium SunCoke Energy's industrial-services pivot is lifting earnings: third-quarter Adjusted EBITDA was $76.9M and 2026 guidance sits above $265M. Shares closed at $10.66 on 10 November 2026; the Granite City 2027 coke agreement settles what…TARSTarsus PharmaceuticalsMedium Tarsus Pharmaceuticals' XDEMVY sales beat the prior quarter and the company raised 2026 guidance to $715–730 million, which supports the case that the eyelid-mite drug can fund the retina pipeline. Growth is slowing and cash fell to $309.6…TASKTaskUsMedium TaskUs's AI Services line grew 27.7% in the third quarter of 2026 and full-year revenue guidance rose to $1.249–1.251 billion, so the shares are modestly more likely to lead the S&P 500 over three months; the fourth-quarter report,…TBITrueblueMedium TrueBlue's staffing recovery is in reported results (third-quarter revenue $520.7 million, fourth-quarter outlook $499–519 million), so the shares are more likely to lead the S&P 500 over three months; the late-February 2027 report tests…TGTXTG TherapeuticsMedium TG Therapeutics' beat-and-raise on 9 November 2026 lifted its 2026 US BRIUMVI guide to $915–920 million, making the shares modestly likely to beat the S&P 500; a fourth-quarter sales ramp and the subcutaneous Phase 3 topline settle it.THCTenet Healthcare Corporation NewMedium Tenet Healthcare is more likely to lead the S&P 500 over three months: hospital margin hit 19.2% and 2026 guidance rose again. The fourth-quarter report, expected around February 2027, shows whether margin holds without a $147 million…TICTIC SolutionsMedium TIC Solutions' recovery case gained its first confirmation on 5 November 2026: Q3 organic growth reached 8.4% and inspection revenue rose about 8.5%, with FY2026 revenue guidance raised. Q4 results and cash, down to $197.9M, settle whether…TKTeekayMedium Teekay Corporation's tanker subsidiary forecast record fourth-quarter 2026 results on 11 November 2026, giving the shares, 16.2% below their October high, a modest edge over the S&P 500; Teekay Tankers' fourth-quarter report in February…TLSTelosMedium Telos Corporation's third-quarter beat and raised 2026 outlook, led by Telos ID and TSA PreCheck volumes, make the shares modestly more likely than not to beat the S&P 500. The first 2027 outlook, expected in early 2027, shows whether…TNDMTandem Diabetes CareMedium Tandem Diabetes Care is modestly more likely to beat the S&P 500 over three months: management said on 5 November 2026 that tubeless Mobi is in late FDA review with approval expected in the fourth quarter. Clearance by 31 December 2026…TNKTeekay TankersMedium Teekay Tankers' third-quarter 2026 beat and its forecast of record fourth-quarter results make the shares modestly likely to beat the S&P 500. Spot tanker rates through the Hormuz disruption and US sanctions policy will settle it.TTMITTM TechnologiesMedium TTM Technologies' record AI data-center board sales (third-quarter revenue $1.204 billion, up 60%) make the shares modestly more likely to beat the S&P 500 over three months after a 45.5% fall; the fourth-quarter report, expected around…TVTXTravere TherapeuticsMedium Travere Therapeutics' FILSPARI kidney-drug sales beat the third-quarter benchmark at $200.2 million, but new patient start forms slipped to 1,932 and Q4 carries an inventory drag. Fourth-quarter sales and the 1 December CEO handover decide…UIUbiquitiMedium Ubiquiti's record $1,026.2M quarter and 47.3% gross margin support the case; the February report settles whether margin survives rising component costs.VACMarriott Vacations WorldwideMedium Marriott Vacations Worldwide is modestly more likely to beat the S&P 500 over three months: third-quarter contract sales rose 29% and 2026 guidance was raised. The 9 December 2026 investor day and the fourth-quarter report in about…VGVenture GlobalMedium Venture Global's shares have a modest edge over the S&P 500 after the company raised its 2026 adjusted EBITDA guide to $10.0–10.3 billion on 10 November 2026. Year-end long-term contracts, the first AI power order and CP2's July 2027 start…VIAVViavi SolutionsMedium Viavi Solutions' fiscal first-quarter beat and a $505–515 million second-quarter revenue guide point to shares that lead the S&P 500 over three months; the fiscal second-quarter report in early February 2027 shows whether revenue delivers…VIRVir BiotechnologyMedium Vir Biotechnology's hepatitis delta regimen met its pivotal ECLIPSE 1 endpoint on 8 November 2026 (44% response versus 0%), so the shares lean toward beating the S&P 500 over three months despite the new stock offering. The ECLIPSE 2 and 3…VRTVertiv HoldingsMedium Vertiv's Q3 2026 report confirmed AI power-and-cooling demand: sales of $4,313M, full-year guide raised to $14,450M–$14,850M. The shares fell on AI-spending fear; the February 2027 report tests the $4,313M–$4,513M Q4 guide.VSHVishay IntertechnologyMedium Vishay Intertechnology's order-led recovery, shown in record revenue and a 25.5% gross margin reported 4 November 2026, makes the shares modestly more likely to lead the S&P 500 over three months; the early-2027 fourth-quarter report…VSTSVestisMedium Vestis Corporation's uniform-rental turnaround is more likely to beat the S&P 500 over three months if cost savings reach fiscal 2026 earnings; the full-year report, expected in early December 2026, shows whether the $310–315 million…WWayfairMedium Wayfair has held a 6.9% adjusted EBITDA margin for two straight quarters as US growth sped up, which leaves its shares modestly likely to beat the S&P 500. The fourth-quarter report decides whether the margin holds while a December rate…WDAYWorkdayMedium Workday's shares are modestly more likely to beat the S&P 500 over three months: a slowing but intact subscription business plus an unconfirmed Silver Lake takeover premium. Results on 24 November 2026 show whether cRPO growth lands inside…WESTWestrock CoffeeMedium Westrock Coffee's shares look modestly more likely to beat the S&P 500 after falling from $10.37 to $8.59 since the 5 November 2026 report, with adjusted EBITDA growing and two analysts raising targets. Early-2027 customer allocations and…WEXMedium WEX Inc. is more likely to beat the S&P 500 over three months on organic fuel-card growth and share repurchases, though fuel prices drove much of its 28 October 2026 beat; the fourth-quarter report, estimated for early February 2027, shows…WPPMedium WPP plc's third-quarter update on 29 October 2026 met the test set for it: like-for-like revenue less pass-through costs fell 2.1% against 2.8% in the second quarter, and 2026 guidance held. The shares, near their 52-week high, now need Q4…WSCWillScot HoldingsMedium WillScot Holdings is more likely to lead the S&P 500 over three months: third-quarter sales of $601.3 million beat estimates and 2026 sales guidance rose to $2.340 billion, while the fourth-quarter report decides whether the 38.8% adjusted…WSMWilliams-SonomaMedium Williams-Sonoma's raised fiscal 2026 outlook and a new round of analyst target raises on 12 November 2026 leave the shares modestly more likely to lead the S&P 500 over three months; the third-quarter report, expected in the second half of…XMTRXometryMedium Xometry's custom-parts marketplace reported 40% revenue growth on 3 November 2026 and raised its 2026 outlook, which leaves the shares modestly more likely than not to beat the S&P 500 over three months. The fourth-quarter report must…XPOMedium XPO, Inc. is more likely than not to beat the S&P 500 over three months: its 80.1% third-quarter LTL operating ratio is a real margin gain. The November operating data, expected around 3 December 2026, shows whether volume and pricing hold.ZBIOZenas BioPharmaMedium Zenas BioPharma is modestly more likely than not to beat the S&P 500 over three months; the SunStone Phase 2 lupus result for obexelimab, guided for the fourth quarter of 2026, settles whether the drug reaches beyond IgG4-RD.ZIPZipRecruiterMedium ZipRecruiter's third-quarter 2026 report beat its own guidance (revenue $124.4M, +8%; 73,929 paying employers), and the shares closed at a 52-week high of $6.59 on 10 November 2026. The fourth-quarter guide of $118–122M decides whether the…ZYMEZymeworksMedium Zymeworks shares have a modest edge over the S&P 500 after the company raised 2026 revenue guidance to $337–351 million on 9 November 2026; Roche antitrust clearance, expected in Q4 2026, and Jazz's next Ziihera sales report settle it.